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ABSTRACT 
Objective: The objective of this EBM review is to determine whether or not Edaravone is 
effective at slowing disease progression in patients with ALS. 
 
Study Design: Review of three randomized control trials. 
 
Data Source: All articles were published in English between 2014 and 2019. Articles were 
obtained from peer-reviewed journals and databases using Cochrane Collaboration, PubMed, 
Medline, and Embase. 
 
Outcomes: The outcome measured was physical function assessed by the Amyotrophic Lateral 
Sclerosis Assessment and Questionnaire 40 Revised (ALSAQ-40R). Patients are asked to 
provide a perceived ability rating on a scale of 0 to 100, with 0 indicating perfect health and 100 
a total loss of function. 
 
Results: The Double bind RCTs of both Abe et al. (Amyotroph Lateral Scler Frontotemporal 
Degener. 2014;15:610-617. Doi: 10.3109/21678421.2014959024.) as well as The Writing Group 
on behalf of the Edaravone (MCI-186) ALS 17 Study Group. (Amyotroph Lateral Scler 
Frontotemporal Degener. 2017;18:20-31. Doi: 10.1080/21678421.2017.1362000) failed to 
demonstrate Edaravone efficacy against placebo (p=0.892 and p=0.1651, respectively). Final 
trial conducted by The Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study 
Group. (Lancet Neurol. 2017;15:505-512. Doi: 10.106/S1474-4422(17)30115-1) found that 
Edaravone was more effective at slowing disease progression than placebo in a well-defined 
patient population (p=0.0309).  
 
Conclusion: A summation of results from three articles reviewed here would indicate that 
Edaravone does not slow disease progression in patients with ALS. There does appear to be 
some utility in early disease patients, but this finding requires further evaluation.   
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INTRODUCTION 
Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive, degenerative motor neuron 
disease affecting both upper and lower tracts, leading to nerve dysfunction, paralysis, and 
ultimately death. Most recent reports indicate and incidence of 0.6 and 3.8 per 100,000 person-
years and a prevalence of 4.1 and 8.4 per 100,000.1 There is a profound degree of ambiguity in 
early disease manifestation. However, it is largely characterized by progressive muscle weakness 
originating in either limb or bulbar tracts; closely followed by atrophy, fasciculations, and 
cramping. Limb onset is most common at 58-82% of patients and traditionally begins at a distal, 
unilateral location and progresses proximally following neuronal distribution.2 The final result 
being total paralysis that spares all sensory function. Mortality frequently occurs due to neurogenic 
respiratory failure. Like early disease symptoms, survival time from diagnosis to death in ALS can 
be highly varied; although most sources would indicate a median survival time from diagnosis is 
3 years.2 Mean age at onset is 58-63 years for sporadic and 40-60 years for familial ALS varieties.2  
A number of articles postulate a relationship between several environmental risk factors 
and ALS development. These include smoking, body mass index, physical exercise, occupational 
and environmental exposures to heavy metals (notably lead), pesticides, b-methylamino-L-alanine, 
head injury and viral infections.3,4 The most explored modifiable risk factor to date is tobacco use 
(smoking) and the most studied non-modifiable risk factors remain male sex and increased age.5 
While research continues to be conducted on these relationships, the causation and pathogenetic 
effect of each remains obscure.3,4,5 
The framework of ALS has shown itself to be exhaustingly convoluted, with variances and 
nuances between and even among distinct demographics. It is widely hypothesized that a genetic 
predisposition and epigenetic collusion prompt number of biopathological alterations. Current 
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literature identifies approximately 20 aberrant genes correlated with disease manifestation.2,3,4 
Despite this, epigenetic collaboration and inter-gene architecture as well as disease penetrance has 
yet to be entirely understood. A number of subsequent biochemical transformations have been 
demonstrated as pervasive features, though far from definitive. Dysregulated RNA processing, 
protein aggregation, mitochondrial dysfunction, neuronal excitotoxicity, and oxidative stress all 
appear as commonalities across ALS pathogenesis research.2,3,4 To add to the complexity of the 
disease, it is ambiguous as to what impact each feature has on the expression of the others.  
Contrasting strides in foundational ALS discoveries, treatment targets have remained 
largely stagnant since Riluzole first became available for ALS patients in 1995. Riluzole is the 
only FDA approved pharmacological intervention other than Edaravone for ALS to date. It 
functions to abate neuronal excitotoxicity as a glutamic acid release inhibitor.6 While Riluzole 
persists as a staple in ALS treatment, clinical trials have only shown the ability to extend time to 
intubation by 2-3 months.2,5-7 The mechanism of action for Edaravone has yet to be solidified. It is 
hypothesized to be a free radical scavenger and has shown oxidant-stress mediating properties in 
mouse-models.7 Thus working on another biochemical feature, not at the gene level, and not 
altogether dissimilar from Riluzole.  
Few articles address the economic burden of ALS within the US. A 2015 systematic review 
approximates $69,475USD per annum; a more recent German analysis suggests the cost can reach 
nearly $300,000USD spent over the course of the disease.8,9 While the total cost of illness (COI) 
may not seem as catastrophic as that of more prevalent diseases, it is important to note these 
expenses are incurred in the span of 2-5 years and carry with them no promise of disease remission 
or resolution. In best case scenarios, the high cost of treatment may only realize life prolongation 
Rutledge, Edaravone Efficacy in ALS Patients 3 
 
 
by a few months. It is reasonable to speculate that the COI remains relatively low due to the lack 
of pharmacological intervention, medication efficacy, and rapid disease progression.  
OBJECTIVE 
The objective of this EBM review is to determine whether Edaravone is effective at 
slowing disease progression in patients with ALS.  
METHODS  
 This review evaluated articles obtained from Cochrane Library, Medline, PubMed, and 
Embase. Online databases were explored via keywords: “ALS,” “amyotrophic lateral sclerosis 
treatment,” “edaravone,” and “ALSAQ-40.” Selection criteria consisted of blinded, randomized 
controlled trials published during or after 2014, either written in or translated into English. 
Included articles had participants with a definitive or probable ALS diagnosis. Intervention 
selected was Edaravone with comparison to placebo control. Initial inclusion criteria consisted of 
articles with self-reported, health-related quality of life outcome measures (HRQoL). Later 
HRQoL was refined specifically to articles in which the Amyotrophic Lateral Sclerosis 
Assessment Questionnaire – 40 revised (ALSAQ40-R) was used to assess outcome measures. 
Articles that evaluated disease-oriented outcome measures, contained unblinded populations or 
evaluators, were post-hoc analysis or included late disease-states (determined by tracheal 
intubation) were excluded.  
 A single author reviewed articles in their entirety for methodological quality, completeness 
of data, adequate randomization, ethical soundness. Initially, 13 met inclusionary criteria and were 
examined. After the outcome measure assessment was refined to ALSAQ-40 alone, these were 
concentrated to the three double-blind, randomized controlled trials (RCT) contained in this 
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review. Each article contained analogous assessment reporting: 1) intergroup mean change from 
baseline, 2) P-value, 3) confidence interval.  
OUTCOMES MEASURED 
The primary outcome measured in all three selected studies was physical ability and 
function and primary endpoint used for analysis was the Amyotrophic Lateral Sclerosis Functional 
Rating Scale – Revised (ALSFRS-R).10-12 However, the ALSFRS-R measures evaluator obtained 
data points and thereby does not meet HRQoL/POEM criteria. Patient perceived function was 
measured as a second endpoint in all three trials and subsequently selected for analysis in this 
review. Patient perceived function was assessed via the Amyotrophic Lateral Sclerosis Assessment 
Questionnaire 40 (revised). The ALSAQ-40R is a self-reported HRQoL questionnaire that assesses 
patients’: A) physical mobility on 10 items. B) activities of daily living and independence on 10 
items. C) eating and drinking ability on 3 items. D) communication on 7 items. E) emotional 
reactions on 10 items. Section parameters are based on a 0 to 100 scale with 0 indicating perfect 
health and 100 indicating a total loss of capacity in dimension.13 
RESULTS 
 In Abe et al. (2014) RCT, 206 patients meeting inclusion criteria (Table 1) were 
randomized via dynamic allocation into placebo (N = 102) or treatment (Edaravone) (N = 104) 
groups.10 Their design consisted of a 12-week pre-observation period followed by a 24-week 
treatment phase, for a total of 36 weeks of data collection. The first treatment cycle involved 14 
days in which Edaravone 60mg was administered daily via intravenous infusion in treatment 
group. Saline was administered for placebo group during this period.10 During treatment cycles 2 
through 6, Edaravone was administered daily for 10 days.10 
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Table 1: Demographics and Characteristics of Included Studies                                                                                                
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Each treatment cycle was followed by a 14-day observation period. Patients prescribed Riluzole 
(N = 182) were required to remain on treatment with the stipulation that no alterations be made to 
pre-trial regimen.10 During the trial, two patients in the placebo group and three in the Edaravone 
group were lost due to death. Analysis of adverse events (AE) and serious adverse event (SAE) 
found no intergroup difference (p=1.000 and p=0.349 respectively).10 As all reported AE and SAE 
fell within the spectrum of normative ALS progression, the authors did not conclude they were 
due to treatment.10 Neither group demonstrated adverse drug reactions. 
 Statistical analysis of efficacy endpoints was calculated via Analysis of Covariance 
(ANCOVA) and reported in least squares mean change, intergroup difference, and p-value.10 
Evaluation revealed an extremely narrow intergroup ALSAQ-40R mean change from baseline of 
0.48 (SD ±3.50; 95% CI: -0.44, 7.39) which failed to meet statistical significance (p = 0.892).10 
 Table 2 - ALSAQ-40R expressed as mean change ± SD from pre-observation to post treatment10 
 
 The second article examined was the Writing Group on Behalf of the Edaravone ALS 17 
Study Group (2017).11 This trial was an extension to ALS Study Group 16. During this follow-
through, the 180 of the original 183 patients who completed the initial 24-week study and failed 
to meet exclusion criteria (Table 1) were enrolled into the extension.11 Treatment group 
assignments during ALS 16 Study were indicated by preceding letter: “E” for Edaravone, “P” for 
placebo. Treatment group assignments during the extension indicated by following letter; “E” for 
Edaravone, “P” for placebo. The final full analysis set (FAS) was comprised of 180 participants 
randomly assigned via minimization method into three groups E-E (N = 48), E-P (N = 44), P-E (N 
= 88).11  Of note, placebo-placebo group was disallowed from extension randomization.  
 Adjusted mean 
change 
Inter-group difference in adjusted mean change 
(95% CI) 
 P-value 
Edaravone 19.6 ± 3.82 0.48 ±3.50 
(- 0.44, 7.39) 
0.892 
Placebo 19.13 ± 3.79 
Statistical significance (P < 0.05)  
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Treatment protocol during the initial trial and its extension was analogous to the 24-week 
design used by Abe et al. (2014) with a caveat that no 12-week pre-observation period was 
incorporated.11 Treatment cycle entailed Edaravone 60 mg IV administered daily for 10 days in E-
E and P-E groups; saline was administered at the same time in E-P group.11 Treatment cycle was 
immediately followed by a 14-day observation period for all participants. Patients prescribed 
Riluzole (N = 161) were required to remain on treatment with the stipulation that no alterations be 
made to pre-trial regimen.11  
The authors noted a statistical difference in E-E versus E-P serious adverse events (SAE) 
between the group (p=0.0344).11 25 of 48 participants (52.1%) of the E-E group while only 13 of 
45 participants in the E-P group developed SAE’s.11 They suggest SAEs were attributable to 
normative ALS progression and not related to serious ADRs. They go on to suggest that an age 
discrepancy existed between E-E and E-P despite minimization allocation. No further attempt to 
establish causation was made.11 
Statistical analysis of efficacy endpoints was calculated via Analysis of Covariance 
(ANCOVA) and reported in least squares mean change, intergroup difference, and p-value.11 
Evaluation revealed an extremely narrow intergroup ALSAQ-40R mean change from baseline of 
-5.45 (SD ±3.89; 95% CI: -13.19, 2.29) which failed to meet statistical significance (p = 0.165).11 
Table 3 – ALSAQ-40R expressed as mean change ± SD from pre-observation to post treatment11 
 
 
 Adjusted mean 
change 
Inter-group difference in adjusted mean change 
(95% CI) 
 P-value 
E-E 13.54 ± 2.89 -5.45 ±3.89 
(- 13.19, 2.29) 
0.1651 
E-P 18.99 ± 3.03 
Statistical significance (P < 0.05)  
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Post-hoc analysis of previous Stage II and III trials suggested that early-stage ALS patients 
may realize more favorable treatment effects compared to later stage patients.12 This prompted 
The Writing Group on Behalf of the Edaravone ALS 19 Study Group (2019) to conduct a trial with 
limited disease progression criteria. Investigators restricted patient demographic to only include 
participants with ALSFRS-R scores of at least 2 in all 12 dimensions, FVC of 80% (opposed to 
70% in previous trials), and shortened disease duration to patients with less than 2 years since first 
symptom (Table 1).12  
After additional exclusion criteria (Table 1) were applied, 134 patients were randomized 
via dynamic allocation by an independent registration center into placebo (N = 66) or treatment 
(Edaravone) (N = 68) groups.12 Their design consisted of a 12-week pre-observation period 
followed by a 24-week treatment phase, for a total of 36 weeks of data collection. The first 
treatment cycle involved 14 days in which Edaravone 60mg was administered daily via 
intravenous infusion in treatment group. Saline in visually matched packaging was administered 
for placebo group during this period. During treatment cycles 2 through 6, Edaravone was 
administered daily for 10 days. Each treatment cycle was followed by a 14-day observation period. 
Patients prescribed Riluzole (N = 182) were required to remain on treatment with the stipulation 
that no alterations be made to pre-trial regimen. 
Statistical analysis of efficacy endpoints was calculated via Analysis of Covariance 
(ANCOVA) and reported in least squares mean change, intergroup difference, and p-value.12 
Evaluation revealed an extremely narrow intergroup ALSAQ-40R mean change from baseline of 
-8.79 (SD ±4.03; 95% CI: -16.76, 0.82) which failed to meet statistical significance (p = 0.0309).12 
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Table 4 - ALSAQ-40R expressed as mean change ± SD from pre-observation to post treatment12 
 
DISCUSSION 
ALS is a disease defined by definite, drastic reduction in life expectancy, rapid progression, 
and lack of treatment options. The combination lends to the sense of absolute futility in patients, 
their families, and their providers. As such, it is an arena of mounting research. Unfortunately for 
the immediate period, much of that research is directed towards uncovering pathogenetic factors 
which may not appreciate effective treatment regimens for some time. In the interim, Edaravone 
is a treatment targeted at oxidative stress, a feature prevalent in nearly all ALS physiological 
research.   
The three articles evaluated in this review had entirely equivalent treatment protocols, 
randomization methods, efficacy determinants, primary and secondary endpoints, and statistical 
analysis. The only deviation in method being the population restriction to early disease states 
implemented in ALS Study 19 (2019).12 Though this final trial exclusively demonstrated efficacy 
(p = 0.0309), the implications of failing to meet statistical significance may be noteworthy.10,11,12  
In their discussion, the authors of ALS Study Group 19 (2019) propose the more robust 
exclusion criteria as a design limitation and go on to question Edaravone’s efficacy in total.12 Their 
suspicion has merit based on results from the previous two trials which failed to show any 
treatment effect (p=0.892; p=0.1651).10,11 However, rudimentary physiology would indicate that 
relieving neuronal oxidative stress would not render any benefit if the neuron were already 
deceased. Subsequently, if Edaravone’s mechanism of action is to mitigate free radicals as 
 Adjusted mean 
change 
Inter-group difference in adjusted mean change 
(95% CI) 
 P-value 
Edaravone 17.25 ± 3.39 -8.79 ± 4.03 
(-16.76, 0.82) 
0.0309 
Placebo 26.04 ± 3.53 
Statistical significance (P < 0.05)  
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hypothesized, one can easily infer that it must be administered early in the disease course, prior to 
neuronal death, in order to have any effect. While that association is speculative on multiple levels, 
it is a logical deduction made more intriguing by the observation of treatment failure with the 
inclusion of moderate disease stage patients. Additional data points are required to support this 
theory. But as Edaravone has been approved by the FDA for use in ALS patients, this hypothesis 
could be easily verified via cost-effective clinical trials employing study designs that parallel those 
reviewed in this article.  
It should be understood that despite reaching statistical significance for efficacy (p=0.0309) 
in ALS Study Group 19 (2019), the treatment effect size remains marginal (intergroup mean 
change: -8.79 ± 4.03; 95% CI: -16.76, 0.82) compared to the ALSAQ-40R total 100-point scale.12 
This lends credit to the authors of ALS Study 19 (2019) suspicions.12 That said, a longitudinal 
study may realize an expansion of intergroup mean changes if Edaravone can continue to abate 
free radicals. As a prevailing notion throughout this review, more data points are required to 
support this hypothesis.  
All three trials appear to be of sound design and free of limitations. As the mean time from 
diagnosis to death is approximately 3 years, an active intervention design of 24-weeks represents 
approximately 15% of total disease duration and is well long enough to determine statistical 
efficacy. However, data collected from extended clinical trials that initiate with early course ALS 
patient must be performed to truly answer the objective sought in this review. Randomization was 
conducted via minimization method, which has grown favor in contemporary oncological trials. 
Minimization method is not true randomization but a restricted, dynamic form of allocation that 
seeks to balance prognostic factors across study arms. This does not appear to have an impact on 
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any of the RCT results as the only trial that met statistical significance employed an independent 
randomization center.11 
ALS researchers, by large, appear to be on correct footing with regards to targeting future 
research. It is readily apparent that mediation of physiological effects subsequent to genetic 
alterations will only manifest marginal, short-term results. This is made obvious by the negligible 
benefit exhibited by Riluzole, as well as the statistical results of the trials reported in this 
review.6,7,10-12 This suggests that prolonged benefit might only be possible with intervention at the 
genetic and epigenetic level. This level of investigation does little in the way of immediate hope 
for ALS patients and their families but provides far better possibilities of uncovering extensive 
disease modification over current treatment targets.   
CONCLUSION  
Analysis of treatment options in ALS appear to be just as opaque as the disease itself. As 
a broad answer to the question presented in this review, Edaravone does not slow disease 
progression in patients with ALS.10,11, Moreover, it is reasonable to near-definitively state that 
Edaravone provides no benefit in  middle to late-stage ALS patients.10,11  However, there does 
seem to be utility in early-stage administration with respect to prolonging physical function.12 The 
duration that function can be maintained has yet to be explored. In summation, there are not enough 
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